CN118647412A - 治疗诊断学叶酸酯缀合物 - Google Patents

治疗诊断学叶酸酯缀合物 Download PDF

Info

Publication number
CN118647412A
CN118647412A CN202380018495.8A CN202380018495A CN118647412A CN 118647412 A CN118647412 A CN 118647412A CN 202380018495 A CN202380018495 A CN 202380018495A CN 118647412 A CN118647412 A CN 118647412A
Authority
CN
China
Prior art keywords
compound
compound according
radiometal
effective amount
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380018495.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·格罗恩
M-L·伦茨
R·莫瑟
R·施布利
C·M·穆勒
L·M·德贝勒
A·E·贝克尔
S·D·巴斯林格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN118647412A publication Critical patent/CN118647412A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380018495.8A 2022-02-01 2023-01-30 治疗诊断学叶酸酯缀合物 Pending CN118647412A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154652 2022-02-01
EP22154652.6 2022-02-01
PCT/EP2023/052117 WO2023148116A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (1)

Publication Number Publication Date
CN118647412A true CN118647412A (zh) 2024-09-13

Family

ID=80118841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380018495.8A Pending CN118647412A (zh) 2022-02-01 2023-01-30 治疗诊断学叶酸酯缀合物

Country Status (9)

Country Link
US (1) US20250127938A1 (enExample)
EP (1) EP4472677A1 (enExample)
JP (1) JP2025504027A (enExample)
KR (1) KR20240146013A (enExample)
CN (1) CN118647412A (enExample)
AU (1) AU2023216406A1 (enExample)
CA (1) CA3243584A1 (enExample)
IL (1) IL314508A (enExample)
WO (1) WO2023148116A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025227100A2 (en) * 2024-04-26 2025-10-30 Purdue Research Foundation Targeted delivery of therapeutic agent to retinal pigment epithelium in treatment of ocular diseases

Also Published As

Publication number Publication date
WO2023148116A1 (en) 2023-08-10
CA3243584A1 (en) 2023-08-10
US20250127938A1 (en) 2025-04-24
AU2023216406A1 (en) 2024-09-19
KR20240146013A (ko) 2024-10-07
EP4472677A1 (en) 2024-12-11
IL314508A (en) 2024-09-01
JP2025504027A (ja) 2025-02-06

Similar Documents

Publication Publication Date Title
JP7393485B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP6152104B2 (ja) アルブミン結合実体のホラートコンジュゲート
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
CN118660723A (zh) 治疗诊断学叶酸酯缀合物
CN118647412A (zh) 治疗诊断学叶酸酯缀合物
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
HK40109744A (zh) 治疗诊断学叶酸酯缀合物
HK40110380A (zh) 治疗诊断学叶酸酯缀合物
JP2024530057A (ja) ネトリン－１検出、コンパニオン検査及び放射線に基づく療法
EP4640240A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
EP4317188A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
WO2025191096A1 (en) Bicyclic peptide
HK40054611A (en) Novel tumor antigen binding agents and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109744

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination